Exposure and Response Prevention with Acceptance and Commitment Therapy for the Treatment of Obsessive Compulsive Disorder

The Research Lab at Portland Psychotherapy is interested in improving our understanding of two treatments for Obsessive Compulsive Disorder (OCD):  gold standard treatment Exposure and Response prevention (ERP) and newer mindfulness and acceptance-based treatment Acceptance and Commitment Therapy. Both ERP and ACT are supported by research as treatments for OCD.

Study Overview

We are working with people struggling with OCD who have not been involved in ERP or ACT treatment in the past.

Qualified participants receive 18 sessions of individual treatment for OCD, including 12 sessions of ERP and 4 session of ACT. There is no cost treatment. Throughout treatment participants are asked to submit daily measures in order to track specific processes in treatment. These assessments will take about 5-10 minutes daily to complete. Additionally, participants will schedule 3 assessment appointments for 1-2 hours each.

Here’s a flyer with the study information if you would like to read more (the study is currently full and not taking new applicants).

Eligibility

To be eligible for this study, you must:

  1. Meet criteria for OCD based on objective assessment measures.
  2. Experience daily obsessions/compulsions.
  3. Be willing to complete all study-related assessments (i.e., before treatment; mid-point; end of treatment).
  4. Be willing to engage in 18 weekly sessions of psychotherapy for OCD.
  5. Be able to read and speak in English
  6. Be 18 years of age or older.

You are not eligible if you:

  1. Have been treated for OCD with Exposure and Response Prevention (ERP) and/or Acceptance and Commitment Therapy (ACT) in the past.
  2. Have a cognitive impairment that would interfere with consent and/or treatment, such as an Autism Spectrum Disorder, psychotic disorder, or developmental disability.
  3. If you are actively taking a benzodiazepine such as Xanax, Lorazepam, or Valium, we ask you discontinue regular use while you are involved in the study, as it may interfere with treatment.